Posted by Michael Wonder on 04 Aug 2024
First time-limited reimbursement recommendation supports earlier patient access to a promising cancer treatment
30 July 2024 - Patients in Canada with advanced-stage lymphoma are one step closer to accessing the first drug to receive a time-limited reimbursement recommendation from Canada’s Drug Agency.
The manufacturer, AbbVie, recently announced the successful completion of negotiations with the pan-Canadian Pharmaceutical Alliance and that a letter of intent has been signed by both parties.
Time-limited recommendations are an example of our efforts to modernise our reimbursement review processes with the goal of supporting timely access to promising new therapies.
